(24) reported two ACCB patients with IDH2 and FGFR2 mutations who were treated with enasidenib and erdafitinib targeted therapies, both of which showed clinical benefit, suggesting that genetic testing plays an important role in the treatment of rare malignant tumors. This evidence concerns the gene FGFR2 and cancer.